 SAN DIEGO, April 12, 2021 GLOBE NEWSWIRE -- Adamis Pharmaceuticals Corporation NASDAQ: ADMP today provided an update on the status of the companys New Drug Application NDA relating to its ZIMHITM high-dose naloxone injection product intended for the treatment of opioid overdose. The company had a Type A meeting with the U.S. Food and Drug Administration FDA to review comments on the additional information provided by the company in response to the FDAs previous Complete Response Letter CRL regarding the NDA, and also to obtain input from the agency concerning the resubmission of the NDA. Adamis believes the meeting was productive and plans to resubmit the NDA for ZIMHI to the FDA within the next 45 days, absent unexpected delays. The FDA did not provide a detailed timeline for review but did indicate that it would attempt to work in an expeditious manner, acknowledging that the country is in an opioid crisis. 